外周血全血长链非编码RNA作为诊断抑郁症的用途

• Format: Patent
• Language: Chinese
• Published: 05.07.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

本发明公开外周血全血长链非编码RNA作为诊断抑郁症的用途，提供外周血中LncRNA在诊断抑郁症中的新用途，通过对抑郁症及健康受试者外周血全血进行全转录组测序，分析抑郁症及健康受试者差异表达LncRNA，然后再通过qRT-PCR进行扩大样本验证；本发明发现的四条LncRNA(AL355075.4-201，AC136475.8-201，AC012076.1-201，SPATA13-AS1-201)在抑郁症及健康受试者外周血全血中的差异表达，作为抑郁症诊断的外周生物分子标志物。 The invention discloses application of peripheral blood whole-blood long-chain non-coding RNA (Ribonucleic Acid) in diagnosis of depression and provides new application of LncRNA in peripheral blood in diagnosis of depression. Whole transcriptome sequencing is carried out on peripheral blood whole blood of depression and healthy subjects, differential expression LncRNA of the depression and the healthy subjects is analyzed, and then expanded sample verification is carried out through qRT-PCR (Quantitative Reverse Transcription-Polymerase Chain Reaction); and according to the application, the difference expression of the four LncRNAs (AL355075.4-201, AC136475.8-201, AC012076.1-201 and SPATA13-AS1-201) found by the invention in the peripheral blood whole blood of depression an